SCHEMBL30310882

SCHEMBL30310882

CC(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(=O)O)C(=O)O

nearest known ligand 0.61

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
▸ CCKBR P32239 14/20 0.61
▸ CXCL8 P10145 5/20 0.56
▸ DPP3 Q9NY33 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30310835 0.91 DPP3 (0.57) CCKBRDPP3
SCHEMBL30310982 0.89 CCKBR (0.61) CCKBRDPP3
SCHEMBL31499421 0.88 DPP3 (0.60) CXCL8DPP3
SCHEMBL30957019 0.88 DPP3 (0.61) DPP3
SCHEMBL31499403 0.87 DPP3 (0.60) CCKBRCXCL8DPP3
SCHEMBL31499422 0.87 DPP3 (0.57) CXCL8DPP3
SCHEMBL30311040 0.86 CCKBR (0.71) CCKBR
SCHEMBL30957021 0.85 DPP3 (0.59) CXCL8DPP3
SCHEMBL29569487 0.85 TACR1 (0.59) CCKBRCXCL8DPP3
SCHEMBL30311066 0.85 CXCL8 (0.63) CCKBRCXCL8DPP3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250296971-A1 GASTRIC INHIBITORY PEPTIDE RECEPTOR LIGANDS 3B PHARMACEUTICALS GMBH (DE) 2025-09-25 — — US claimed
CN-118632858-A Gastric inhibitory peptide receptor ligands 3B制药有限公司 2024-09-10 — — CN claimed
EP-4423110-A2 GASTRIC INHIBITORY PEPTIDE RECEPTOR LIGANDS 3B Pharmaceuticals GmbH (DE) 2024-09-04 — — EP claimed
WO-2023072971-A2 GASTRIC INHIBITORY PEPTIDE RECEPTOR LIGANDS 3B PHARMACEUTICALS GMBH (DE) 2023-05-04 — — WO claimed
US-20250296971-A1 GASTRIC INHIBITORY PEPTIDE RECEPTOR LIGANDS 3B PHARMACEUTICALS GMBH (DE) 2025-09-25 — — US disclosed
CN-118632858-A Gastric inhibitory peptide receptor ligands 3B制药有限公司 2024-09-10 — — CN disclosed
EP-4423110-A2 GASTRIC INHIBITORY PEPTIDE RECEPTOR LIGANDS 3B Pharmaceuticals GmbH (DE) 2024-09-04 — — EP disclosed
WO-2023072971-A2 GASTRIC INHIBITORY PEPTIDE RECEPTOR LIGANDS 3B PHARMACEUTICALS GMBH (DE) 2023-05-04 — — WO disclosed
EP-4170347-A1 GASTRIC INHIBITORY PEPTIDE RECEPTOR LIGANDS 3B Pharmaceuticals GmbH (DE) 2023-04-26 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250296971-A1 GASTRIC INHIBITORY PEPTIDE RECEPTOR LIGANDS GIPR, VIP, GRPR CCKBR 4/4885CXCL8 1597/4885DPP3 1553/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback